• +1-646-491-9876
    • +91-20-67278686

    Search

    Melanoma Pipeline Review H1 2017

    Melanoma Pipeline Review H1 2017

    • Report Code ID: RW0001866818
    • Category Pharmaceuticals
    • No. of Pages 1779
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Melanoma - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Melanoma - Pipeline Review, H1 2017, provides an overview of the Melanoma (Oncology) pipeline landscape.

    Melanoma is a tumor that develops as a result of the malignant transformation of melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. In women, the most common site is the legs and melanomas in men are most common on the back. Unusual moles, sores, lumps, blemishes, markings, or changes in the way an area of the skin looks or feels are sign of melanoma. Treatment includes surgery, radiation and proton therapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Melanoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Melanoma (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 20, 105, 120, 7, 214, 29 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 14, 13, 1, 62 and 14 molecules, respectively.

    Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Melanoma (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Melanoma (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Melanoma (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Melanoma (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    Introduction 11
    Melanoma - Overview 12
    Melanoma - Therapeutics Development 13
    Melanoma - Therapeutics Assessment 71
    Melanoma - Companies Involved in Therapeutics Development 103
    Melanoma - Drug Profiles 230
    Melanoma - Dormant Projects 1675
    Melanoma - Discontinued Products 1701
    Melanoma - Product Development Milestones 1705
    Appendix 1721

    List of Tables

    Number of Products under Development for Melanoma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..5) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..6) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..7) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..8) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..9) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..10) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..11) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..12) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..13) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..14) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..15) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..16) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017 (Contd..4) , H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..5) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..6) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..7) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..8) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..9) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..10) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..11) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..12) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..13) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..14) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..15) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..16) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..17) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..18) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..19) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..20) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..21) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..22) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..23) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..24) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..25) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..26) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..2) , H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..3) , H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..4) , H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..5) , H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..4) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..5) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..6) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..7) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..8) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..9) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..10) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..11) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..12) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..9) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..10) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..11) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017 (Contd..1) , H1 2017
    Melanoma - Pipeline by 4P-Pharma SAS, H1 2017
    Melanoma - Pipeline by 4SC AG, H1 2017
    Melanoma - Pipeline by AB Science SA, H1 2017
    Melanoma - Pipeline by AbbVie Inc, H1 2017
    Melanoma - Pipeline by Abivax SA, H1 2017
    Melanoma - Pipeline by Adaptimmune Therapeutics Plc, H1 2017
    Melanoma - Pipeline by Aduro BioTech Inc, H1 2017
    Melanoma - Pipeline by Advanced Cancer Therapeutics LLC, H1 2017
    Melanoma - Pipeline by Affichem SA, H1 2017
    Melanoma - Pipeline by Agenus Inc, H1 2017
    Melanoma - Pipeline by AGV Discovery SAS, H1 2017
    Melanoma - Pipeline by AIMM Therapeutics BV, H1 2017
    Melanoma - Pipeline by Alethia Biotherapeutics Inc, H1 2017
    Melanoma - Pipeline by Alkermes Plc, H1 2017
    Melanoma - Pipeline by Altor BioScience Corp, H1 2017
    Melanoma - Pipeline by Amgen Inc, H1 2017
    Melanoma - Pipeline by Anavex Life Sciences Corp, H1 2017
    Melanoma - Pipeline by Angimmune LLC, H1 2017
    Melanoma - Pipeline by Antibe Therapeutics Inc, H1 2017
    Melanoma - Pipeline by Antigen Express Inc, H1 2017
    Melanoma - Pipeline by APEIRON Biologics AG, H1 2017
    Melanoma - Pipeline by Apexigen Inc, H1 2017
    Melanoma - Pipeline by Aphios Corp, H1 2017
    Melanoma - Pipeline by Apogenix GmbH, H1 2017
    Melanoma - Pipeline by Aposense Ltd, H1 2017
    Melanoma - Pipeline by Aptose Biosciences Inc, H1 2017
    Melanoma - Pipeline by ARMO Biosciences Inc, H1 2017
    Melanoma - Pipeline by Array BioPharma Inc, H1 2017
    Melanoma - Pipeline by Asana BioSciences LLC, H1 2017
    Melanoma - Pipeline by Astellas Pharma Inc, H1 2017
    Melanoma - Pipeline by Astex Pharmaceuticals Inc, H1 2017
    Melanoma - Pipeline by AstraZeneca Plc, H1 2017
    Melanoma - Pipeline by Aurigene Discovery Technologies Ltd, H1 2017
    Melanoma - Pipeline by Autotelic Inc, H1 2017
    Melanoma - Pipeline by Basilea Pharmaceutica Ltd, H1 2017
    Melanoma - Pipeline by Batu Biologics Inc, H1 2017
    Melanoma - Pipeline by Bayer AG, H1 2017
    Melanoma - Pipeline by BeiGene (Beijing) Co Ltd, H1 2017
    Melanoma - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H1 2017
    Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017
    Melanoma - Pipeline by BerGenBio ASA, H1 2017
    Melanoma - Pipeline by Bio-Cancer Treatment International Ltd, H1 2017
    Melanoma - Pipeline by Biocad, H1 2017
    Melanoma - Pipeline by Biogazelle NV, H1 2017
    Melanoma - Pipeline by BioLineRx Ltd, H1 2017
    Melanoma - Pipeline by Bioncotech Therapeutics SL, H1 2017
    Melanoma - Pipeline by Bionomics Ltd, H1 2017
    Melanoma - Pipeline by BioNTech AG, H1 2017
    Melanoma - Pipeline by Biothera Pharmaceutical Inc, H1 2017
    Melanoma - Pipeline by Biovista Inc, H1 2017
    Melanoma - Pipeline by Boehringer Ingelheim GmbH, H1 2017
    Melanoma - Pipeline by Boston Biomedical Inc, H1 2017
    Melanoma - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Melanoma - Pipeline by Calithera Biosciences Inc, H1 2017
    Melanoma - Pipeline by Can-Fite BioPharma Ltd, H1 2017
    Melanoma - Pipeline by CCRP Therapeutics GmbH, H1 2017
    Melanoma - Pipeline by Celgene Corp, H1 2017
    Melanoma - Pipeline by Celldex Therapeutics Inc, H1 2017
    Melanoma - Pipeline by Celprogen Inc, H1 2017
    Melanoma - Pipeline by Celyad SA, H1 2017
    Melanoma - Pipeline by Checkmate Pharmaceuticals Inc, H1 2017
    Melanoma - Pipeline by Chipscreen Biosciences Ltd, H1 2017
    Melanoma - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017
    Melanoma - Pipeline by Cipher Pharmaceuticals Inc, H1 2017
    Melanoma - Pipeline by Corvus Pharmaceuticals Inc, H1 2017
    Melanoma - Pipeline by CytomX Therapeutics Inc, H1 2017
    Melanoma - Pipeline by Cytori Therapeutics Inc, H1 2017
    Melanoma - Pipeline by Cytune Pharma SAS, H1 2017
    Melanoma - Pipeline by CyTuVax BV, H1 2017
    Melanoma - Pipeline by CZ BioMed Corp, H1 2017
    Melanoma - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
    Melanoma - Pipeline by Deciphera Pharmaceuticals LLC, H1 2017
    Melanoma - Pipeline by DEKK-TEC Inc, H1 2017
    Melanoma - Pipeline by Dicerna Pharmaceuticals Inc, H1 2017
    Melanoma - Pipeline by Dynavax Technologies Corp, H1 2017
    Melanoma - Pipeline by Eisai Co Ltd, H1 2017
    Melanoma - Pipeline by Eli Lilly and Company, H1 2017
    Melanoma - Pipeline by Elsalys Biotech SAS, H1 2017
    Melanoma - Pipeline by Ensol Biosciences Inc, H1 2017
    Melanoma - Pipeline by EntreChem SL, H1 2017
    Melanoma - Pipeline by eTheRNA Immunotherapies NV, H1 2017
    Melanoma - Pipeline by Exelixis Inc, H1 2017
    Melanoma - Pipeline by Exicure Inc, H1 2017
    Melanoma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Melanoma - Pipeline by Faron Pharmaceuticals Oy, H1 2017
    Melanoma - Pipeline by Galapagos NV, H1 2017
    Melanoma - Pipeline by Galectin Therapeutics Inc, H1 2017
    Melanoma - Pipeline by Genelux Corp, H1 2017
    Melanoma - Pipeline by Genocea Biosciences Inc, H1 2017
    Melanoma - Pipeline by Genzyme Corp, H1 2017
    Melanoma - Pipeline by GlaxoSmithKline Plc, H1 2017
    Melanoma - Pipeline by Gradalis Inc, H1 2017
    Melanoma - Pipeline by GreenPeptide Co Ltd, H1 2017
    Melanoma - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2017
    Melanoma - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
    Melanoma - Pipeline by Heat Biologics Inc, H1 2017
    Melanoma - Pipeline by Hemispherx Biopharma Inc, H1 2017
    Melanoma - Pipeline by Histogen Inc, H1 2017
    Melanoma - Pipeline by HitGen LTD, H1 2017
    Melanoma - Pipeline by Horizon Pharma Plc, H1 2017
    Melanoma - Pipeline by Humorigin Biotechnology Corp, H1 2017
    Melanoma - Pipeline by Idera Pharmaceuticals Inc, H1 2017
    Melanoma - Pipeline by Ignyta Inc, H1 2017
    Melanoma - Pipeline by Immodulon Therapeutics Ltd, H1 2017
    Melanoma - Pipeline by Immune Design Corp, H1 2017
    Melanoma - Pipeline by Immune Response BioPharma Inc, H1 2017
    Melanoma - Pipeline by ImmunGene Inc, H1 2017
    Melanoma - Pipeline by Immunocore Ltd, H1 2017
    Melanoma - Pipeline by ImmunoGen Inc, H1 2017
    Melanoma - Pipeline by Immupharma Plc, H1 2017
    Melanoma - Pipeline by IMPACT Therapeutics Inc, H1 2017
    Melanoma - Pipeline by Imugene Ltd, H1 2017
    Melanoma - Pipeline by Incyte Corp, H1 2017
    Melanoma - Pipeline by Infinity Pharmaceuticals Inc, H1 2017
    Melanoma - Pipeline by Innovation Pharmaceuticals Inc, H1 2017
    Melanoma - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
    Melanoma - Pipeline by InteRNA Technologies BV, H1 2017
    Melanoma - Pipeline by Intezyne Technologies Inc, H1 2017
    Melanoma - Pipeline by IO Biotech ApS, H1 2017
    Melanoma - Pipeline by JHL Biotech Inc, H1 2017
    Melanoma - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
    Melanoma - Pipeline by Johnson & Johnson, H1 2017
    Melanoma - Pipeline by K-Stemcell Co Ltd, H1 2017
    Melanoma - Pipeline by KaloBios Pharmaceuticals Inc, H1 2017
    Melanoma - Pipeline by Kancera AB, H1 2017
    Melanoma - Pipeline by Karyopharm Therapeutics Inc, H1 2017
    Melanoma - Pipeline by Kite Pharma Inc, H1 2017
    Melanoma - Pipeline by Leap Therapeutics Inc, H1 2017
    Melanoma - Pipeline by Lentigen Technology Inc, H1 2017
    Melanoma - Pipeline by Lindis Biotech GmbH, H1 2017
    Melanoma - Pipeline by Lion Biotechnologies Inc, H1 2017
    Melanoma - Pipeline by Lipotek Pty Ltd, H1 2017
    Melanoma - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017
    Melanoma - Pipeline by Loxo Oncology Inc, H1 2017
    Melanoma - Pipeline by Lupin Ltd, H1 2017
    Melanoma - Pipeline by Lytix Biopharma AS, H1 2017
    Melanoma - Pipeline by MabVax Therapeutics Holdings Inc, H1 2017
    Melanoma - Pipeline by MacroGenics Inc, H1 2017
    Melanoma - Pipeline by Magnus Life Ltd, H1 2017
    Melanoma - Pipeline by MaxiVAX SA, H1 2017
    Melanoma - Pipeline by MediaPharma Srl, H1 2017
    Melanoma - Pipeline by Medicenna Therapeutics Corp, H1 2017
    Melanoma - Pipeline by MedImmune LLC, H1 2017
    Melanoma - Pipeline by MELEMA Pharma GmbH, H1 2017
    Melanoma - Pipeline by Merck & Co Inc, H1 2017
    Melanoma - Pipeline by Merck KGaA, H1 2017
    Melanoma - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
    Melanoma - Pipeline by Molecular Templates Inc, H1 2017
    Melanoma - Pipeline by Moleculin Biotech Inc, H1 2017
    Melanoma - Pipeline by Morphotek Inc, H1 2017
    Melanoma - Pipeline by NantKwest Inc, H1 2017
    Melanoma - Pipeline by Nektar Therapeutics, H1 2017
    Melanoma - Pipeline by Neonc Technologies Inc, H1 2017
    Melanoma - Pipeline by Nerviano Medical Sciences Srl, H1 2017
    Melanoma - Pipeline by Neumedicines Inc, H1 2017
    Melanoma - Pipeline by NewLink Genetics Corp, H1 2017
    Melanoma - Pipeline by NormOxys Inc, H1 2017
    Melanoma - Pipeline by Northwest Biotherapeutics Inc, H1 2017
    Melanoma - Pipeline by Novartis AG, H1 2017
    Melanoma - Pipeline by Novogen Ltd, H1 2017
    Melanoma - Pipeline by Omeros Corp, H1 2017
    Melanoma - Pipeline by Oncology Research International Ltd, H1 2017
    Melanoma - Pipeline by Oncolys BioPharma Inc, H1 2017
    Melanoma - Pipeline by Oncolytics Biotech Inc, H1 2017
    Melanoma - Pipeline by OncoNOx ApS, H1 2017
    Melanoma - Pipeline by OncoSec Medical Inc, H1 2017
    Melanoma - Pipeline by OncoTartis Inc, H1 2017
    Melanoma - Pipeline by Oncovir Inc, H1 2017
    Melanoma - Pipeline by Onxeo SA, H1 2017
    Melanoma - Pipeline by Opsona Therapeutics Ltd, H1 2017
    Melanoma - Pipeline by Orega Biotech SAS, H1 2017
    Melanoma - Pipeline by OSE Immunotherapeutics, H1 2017
    Melanoma - Pipeline by Pacific Northwest Biotechnology LLC, H1 2017
    Melanoma - Pipeline by Patrys Ltd, H1 2017
    Melanoma - Pipeline by PepVax Inc, H1 2017
    Melanoma - Pipeline by Peregrine Pharmaceuticals Inc, H1 2017
    Melanoma - Pipeline by Pfizer Inc, H1 2017
    Melanoma - Pipeline by Pharmicell Co Ltd, H1 2017
    Melanoma - Pipeline by Pharminox Ltd, H1 2017
    Melanoma - Pipeline by Pharmis Biofarmaceutica Lda, H1 2017
    Melanoma - Pipeline by Philogen SpA, H1 2017
    Melanoma - Pipeline by PinCell srl, H1 2017
    Melanoma - Pipeline by Pivotal BioSciences Inc, H1 2017
    Melanoma - Pipeline by Plexxikon Inc, H1 2017
    Melanoma - Pipeline by Polaris Pharmaceuticals Inc, H1 2017
    Melanoma - Pipeline by Polyplus-Transfection SA, H1 2017
    Melanoma - Pipeline by Prima BioMed Ltd, H1 2017
    Melanoma - Pipeline by Primevax Immuno Oncology Inc, H1 2017
    Melanoma - Pipeline by Propanac Biopharma Inc, H1 2017
    Melanoma - Pipeline by Provectus Biopharmaceuticals Inc, H1 2017
    Melanoma - Pipeline by Provenance Biopharmaceuticals Corp, H1 2017
    Melanoma - Pipeline by Qu Biologics Inc, H1 2017
    Melanoma - Pipeline by Rafael Pharmaceuticals Inc, H1 2017
    Melanoma - Pipeline by Reata Pharmaceuticals Inc, H1 2017
    Melanoma - Pipeline by Recepta Biopharma SA, H1 2017
    Melanoma - Pipeline by Recombio SL, H1 2017
    Melanoma - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
    Melanoma - Pipeline by Rexahn Pharmaceuticals Inc, H1 2017
    Melanoma - Pipeline by Rgenix Inc, H1 2017
    Melanoma - Pipeline by Rubicon Biotechnology Inc, H1 2017
    Melanoma - Pipeline by RXi Pharmaceuticals Corp, H1 2017
    Melanoma - Pipeline by Sanofi, H1 2017
    Melanoma - Pipeline by SATT North SAS, H1 2017
    Melanoma - Pipeline by Scancell Holdings Plc, H1 2017
    Melanoma - Pipeline by SilaGene Inc, H1 2017
    Melanoma - Pipeline by Sillajen Biotherapeutics, H1 2017
    Melanoma - Pipeline by SolaranRx Inc, H1 2017
    Melanoma - Pipeline by Sorrento Therapeutics Inc, H1 2017
    Melanoma - Pipeline by Spotlight Innovation Inc, H1 2017
    Melanoma - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
    Melanoma - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
    Melanoma - Pipeline by Susavion Biosciences Inc, H1 2017
    Melanoma - Pipeline by SuviCa Inc, H1 2017
    Melanoma - Pipeline by Syndax Pharmaceuticals Inc, H1 2017
    Melanoma - Pipeline by Synthon Holdings BV, H1 2017
    Melanoma - Pipeline by Syntrix Biosystems Inc, H1 2017
    Melanoma - Pipeline by Tactiva Therapeutics LLC, H1 2017
    Melanoma - Pipeline by Taiga Biotechnologies Inc, H1 2017
    Melanoma - Pipeline by Taiwan Liposome Company Ltd, H1 2017
    Melanoma - Pipeline by Takara Bio Inc, H1 2017
    Melanoma - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
    Melanoma - Pipeline by Takis Srl, H1 2017
    Melanoma - Pipeline by Targovax ASA, H1 2017
    Melanoma - Pipeline by TC BioPharm Ltd, H1 2017
    Melanoma - Pipeline by Theravectys SA, H1 2017
    Melanoma - Pipeline by Tikcro Technologies Ltd, H1 2017
    Melanoma - Pipeline by TILT Biotherapeutics Ltd, H1 2017
    Melanoma - Pipeline by Tiltan Pharma Ltd, H1 2017
    Melanoma - Pipeline by Tocagen Inc, H1 2017
    Melanoma - Pipeline by TREAT U SA, H1 2017
    Melanoma - Pipeline by TVAX Biomedical Inc, H1 2017
    Melanoma - Pipeline by UbiVac LLC, H1 2017
    Melanoma - Pipeline by Ultimovacs AS, H1 2017
    Melanoma - Pipeline by UNC Health Care, H1 2017
    Melanoma - Pipeline by Vaccibody AS, H1 2017
    Melanoma - Pipeline by Vascular Biogenics Ltd, H1 2017
    Melanoma - Pipeline by Vault Pharma Inc, H1 2017
    Melanoma - Pipeline by Vaxenta Biotechnologies, H1 2017
    Melanoma - Pipeline by Vichem Chemie Research Ltd, H1 2017
    Melanoma - Pipeline by ViiV Healthcare Ltd, H1 2017
    Melanoma - Pipeline by Viralytics Ltd, H1 2017
    Melanoma - Pipeline by ViraTherapeutics GmbH, H1 2017
    Melanoma - Pipeline by VLP Therapeutics LLC, H1 2017
    Melanoma - Pipeline by WntResearch AB, H1 2017
    Melanoma - Pipeline by X4 Pharmaceuticals Inc, H1 2017
    Melanoma - Pipeline by Zestagen SA, H1 2017
    Melanoma - Dormant Projects, H1 2017
    Melanoma - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Melanoma - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Melanoma - Dormant Projects, H1 2017 (Contd..3) , H1 2017
    Melanoma - Dormant Projects, H1 2017 (Contd..4) , H1 2017
    Melanoma - Dormant Projects, H1 2017 (Contd..5) , H1 2017
    Melanoma - Dormant Projects, H1 2017 (Contd..6) , H1 2017
    Melanoma - Dormant Projects, H1 2017 (Contd..7) , H1 2017
    Melanoma - Dormant Projects, H1 2017 (Contd..8) , H1 2017
    Melanoma - Dormant Projects, H1 2017 (Contd..9) , H1 2017
    Melanoma - Dormant Projects, H1 2017 (Contd..10) , H1 2017
    Melanoma - Dormant Projects, H1 2017 (Contd..11) , H1 2017
    Melanoma - Dormant Projects, H1 2017 (Contd..12) , H1 2017
    Melanoma - Dormant Projects, H1 2017 (Contd..13) , H1 2017
    Melanoma - Dormant Projects, H1 2017 (Contd..14) , H1 2017
    Melanoma - Dormant Projects, H1 2017 (Contd..15) , H1 2017
    Melanoma - Dormant Projects, H1 2017 (Contd..16) , H1 2017
    Melanoma - Dormant Projects, H1 2017 (Contd..17) , H1 2017
    Melanoma - Dormant Projects, H1 2017 (Contd..18) , H1 2017
    Melanoma - Dormant Projects, H1 2017 (Contd..19) , H1 2017
    Melanoma - Dormant Projects, H1 2017 (Contd..20) , H1 2017
    Melanoma - Dormant Projects, H1 2017 (Contd..21) , H1 2017
    Melanoma - Dormant Projects, H1 2017 (Contd..22) , H1 2017
    Melanoma - Dormant Projects, H1 2017 (Contd..23) , H1 2017
    Melanoma - Discontinued Products, H1 2017
    Melanoma - Discontinued Products, H1 2017 (Contd..1) , H1 2017
    Melanoma - Discontinued Products, H1 2017 (Contd..2) , H1 2017
    Melanoma - Discontinued Products, H1 2017 (Contd..3) , H1 2017

    List of Figures

    Number of Products under Development for Melanoma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Top 10 Routes of Administration, H1 2017
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    4P-Pharma SAS
    4SC AG
    AB Science SA
    AbbVie Inc
    Abivax SA
    Adaptimmune Therapeutics Plc
    Aduro BioTech Inc
    Advanced Cancer Therapeutics LLC
    Affichem SA
    Agenus Inc
    AGV Discovery SAS
    AIMM Therapeutics BV
    Alethia Biotherapeutics Inc
    Alkermes Plc
    Altor BioScience Corp
    Amgen Inc
    Anavex Life Sciences Corp
    Angimmune LLC
    Antibe Therapeutics Inc
    Antigen Express Inc
    APEIRON Biologics AG
    Apexigen Inc
    Aphios Corp
    Apogenix GmbH
    Aposense Ltd
    Aptose Biosciences Inc
    ARMO Biosciences Inc
    Array BioPharma Inc
    Asana BioSciences LLC
    Astellas Pharma Inc
    Astex Pharmaceuticals Inc
    AstraZeneca Plc
    Aurigene Discovery Technologies Ltd
    Autotelic Inc
    Basilea Pharmaceutica Ltd
    Batu Biologics Inc
    Bayer AG
    BeiGene (Beijing) Co Ltd
    Beijing Kawin Technology Share-Holding Co Ltd
    Bellicum Pharmaceuticals Inc
    BerGenBio ASA
    Bio-Cancer Treatment International Ltd
    Biocad
    Biogazelle NV
    BioLineRx Ltd
    Bioncotech Therapeutics SL
    Bionomics Ltd
    BioNTech AG
    Biothera Pharmaceutical Inc
    Biovista Inc
    Boehringer Ingelheim GmbH
    Boston Biomedical Inc
    Bristol-Myers Squibb Company
    Calithera Biosciences Inc
    Can-Fite BioPharma Ltd
    CCRP Therapeutics GmbH
    Celgene Corp
    Celldex Therapeutics Inc
    Celprogen Inc
    Celyad SA
    Checkmate Pharmaceuticals Inc
    Chipscreen Biosciences Ltd
    Chugai Pharmaceutical Co Ltd
    Cipher Pharmaceuticals Inc
    Corvus Pharmaceuticals Inc
    CytomX Therapeutics Inc
    Cytori Therapeutics Inc
    Cytune Pharma SAS
    CyTuVax BV
    CZ BioMed Corp
    Daiichi Sankyo Company Ltd
    Deciphera Pharmaceuticals LLC
    DEKK-TEC Inc
    Dicerna Pharmaceuticals Inc
    Dynavax Technologies Corp
    Eisai Co Ltd
    Eli Lilly and Company
    Elsalys Biotech SAS
    Ensol Biosciences Inc
    EntreChem SL
    eTheRNA Immunotherapies NV
    Exelixis Inc
    Exicure Inc
    F. Hoffmann-La Roche Ltd
    Faron Pharmaceuticals Oy
    Galapagos NV
    Galectin Therapeutics Inc
    Genelux Corp
    Genocea Biosciences Inc
    Genzyme Corp
    GlaxoSmithKline Plc
    Gradalis Inc
    GreenPeptide Co Ltd
    Hadasit Medical Research Services & Development Ltd
    Hanmi Pharmaceuticals Co Ltd
    Heat Biologics Inc
    Hemispherx Biopharma Inc
    Histogen Inc
    HitGen LTD
    Horizon Pharma Plc
    Humorigin Biotechnology Corp
    Idera Pharmaceuticals Inc
    Ignyta Inc
    Immodulon Therapeutics Ltd
    Immune Design Corp
    Immune Response BioPharma Inc
    ImmunGene Inc
    Immunocore Ltd
    ImmunoGen Inc
    Immupharma Plc
    IMPACT Therapeutics Inc
    Imugene Ltd
    Incyte Corp
    Infinity Pharmaceuticals Inc
    Innovation Pharmaceuticals Inc
    Inovio Pharmaceuticals Inc
    InteRNA Technologies BV
    Intezyne Technologies Inc
    IO Biotech ApS
    JHL Biotech Inc
    Jiangsu Hengrui Medicine Co Ltd
    Johnson & Johnson
    K-Stemcell Co Ltd
    KaloBios Pharmaceuticals Inc
    Kancera AB
    Karyopharm Therapeutics Inc
    Kite Pharma Inc
    Leap Therapeutics Inc
    Lentigen Technology Inc
    Lindis Biotech GmbH
    Lion Biotechnologies Inc
    Lipotek Pty Ltd
    Lixte Biotechnology Holdings Inc
    Loxo Oncology Inc
    Lupin Ltd
    Lytix Biopharma AS
    MabVax Therapeutics Holdings Inc
    MacroGenics Inc
    Magnus Life Ltd
    MaxiVAX SA
    MediaPharma Srl
    Medicenna Therapeutics Corp
    MedImmune LLC
    MELEMA Pharma GmbH
    Merck & Co Inc
    Merck KGaA
    Millennium Pharmaceuticals Inc
    Molecular Templates Inc
    Moleculin Biotech Inc
    Morphotek Inc
    NantKwest Inc
    Nektar Therapeutics
    Neonc Technologies Inc
    Nerviano Medical Sciences Srl
    Neumedicines Inc
    NewLink Genetics Corp
    NormOxys Inc
    Northwest Biotherapeutics Inc
    Novartis AG
    Novogen Ltd
    Omeros Corp
    Oncology Research International Ltd
    Oncolys BioPharma Inc
    Oncolytics Biotech Inc
    OncoNOx ApS
    OncoSec Medical Inc
    OncoTartis Inc
    Oncovir Inc
    Onxeo SA
    Opsona Therapeutics Ltd
    Orega Biotech SAS
    OSE Immunotherapeutics
    Pacific Northwest Biotechnology LLC
    Patrys Ltd
    PepVax Inc
    Peregrine Pharmaceuticals Inc
    Pfizer Inc
    Pharmicell Co Ltd
    Pharminox Ltd
    Pharmis Biofarmaceutica Lda
    Philogen SpA
    PinCell srl
    Pivotal BioSciences Inc
    Plexxikon Inc
    Polaris Pharmaceuticals Inc
    Polyplus-Transfection SA
    Prima BioMed Ltd
    Primevax Immuno Oncology Inc
    Propanac Biopharma Inc
    Provectus Biopharmaceuticals Inc
    Provenance Biopharmaceuticals Corp
    Qu Biologics Inc
    Rafael Pharmaceuticals Inc
    Reata Pharmaceuticals Inc
    Recepta Biopharma SA
    Recombio SL
    Regeneron Pharmaceuticals Inc
    Rexahn Pharmaceuticals Inc
    Rgenix Inc
    Rubicon Biotechnology Inc
    RXi Pharmaceuticals Corp
    Sanofi
    SATT North SAS
    Scancell Holdings Plc
    SilaGene Inc
    Sillajen Biotherapeutics
    SolaranRx Inc
    Sorrento Therapeutics Inc
    Spotlight Innovation Inc
    Sumitomo Dainippon Pharma Co Ltd
    Sun Pharma Advanced Research Company Ltd
    Susavion Biosciences Inc
    SuviCa Inc
    Syndax Pharmaceuticals Inc
    Synthon Holdings BV
    Syntrix Biosystems Inc
    Tactiva Therapeutics LLC
    Taiga Biotechnologies Inc
    Taiwan Liposome Company Ltd
    Takara Bio Inc
    Takeda Pharmaceutical Company Ltd
    Takis Srl
    Targovax ASA
    TC BioPharm Ltd
    Theravectys SA
    Tikcro Technologies Ltd
    TILT Biotherapeutics Ltd
    Tiltan Pharma Ltd
    Tocagen Inc
    TREAT U SA
    TVAX Biomedical Inc
    UbiVac LLC
    Ultimovacs AS
    UNC Health Care
    Vaccibody AS
    Vascular Biogenics Ltd
    Vault Pharma Inc
    Vaxenta Biotechnologies
    Vichem Chemie Research Ltd
    ViiV Healthcare Ltd
    Viralytics Ltd
    ViraTherapeutics GmbH
    VLP Therapeutics LLC
    WntResearch AB
    X4 Pharmaceuticals Inc
    Zestagen SA

    Request for Sample

    Report Url https://www.reportsweb.com//melanoma-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//melanoma-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//melanoma-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments